Figure 3.

Predictors of benefit to sacituzumab govitecan and berzosertib combination A: RNA sequencing of tumors from patients with clinical benefit (n=2) and without clinical benefit (n=5). GSEA using the Hallmark signature showed that tumors with clinical benefit were enriched for genes associated with replication stress and proliferation and were de-enriched for immune and inflammatory pathways. B: GSEA using the Hallmarks of Cancers signature showing that tumors with clinical benefit were enriched for pathways associated with genome instability. C: Summary of whole exome sequencing results. Blue squares indicate presence of a gene mutation in tumor tissue, with germline mutations indicated by a yellow asterisk. D. Trop-2 IHC from Patient 8 with SCLC transformed from EGFR-mutated NSCLC showed minimal expression. Patients 11 (E) and 1 (F) with NEPC both had IHC with high Trop2 expression.

GSEA: gene set enrichment analysis

NES: normalized enrichment score

SCLC: small cell lung cancer

NSCLC: non-small cell lung cancer

t-SCLC: transformed SCLC